36061-08-2

Basic information

• Product Name: D-2-AMINO-5-PHENYL-PENTANOIC ACID
• Synonyms: H-D-NVA(5-PHENYL)-OH;(R)-2-AMINO-5-PHENYL-PENTANOIC ACID;Benzenepentanoic acid, a-aMino-, (aR)-
• CAS NO: 36061-08-2
• Molecular Formula: C₁₁H₁₅NO₂
• Molecular Weight: 193.24
• Mol File: 36061-08-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 375.2 °C at 760 mmHg
• Flash Point: 180.7 °C
• Appearance: /
• Density: 1.133g/cm³
• Vapor Pressure: 2.69E-06mmHg at 25°C
• Refractive Index: 1.555
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: D-2-AMINO-5-PHENYL-PENTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: D-2-AMINO-5-PHENYL-PENTANOIC ACID(36061-08-2)
• EPA Substance Registry System: D-2-AMINO-5-PHENYL-PENTANOIC ACID(36061-08-2)

Safety Data

• Hazardous Substances Data: 36061-08-2(Hazardous Substances Data)

Usage

General Description

D-2-Amino-5-Phenyl-Pentanoic Acid, also known as D-Phenylalanine, is a chemical compound categorized as an essential α-amino acid with the chemical formula C9H11NO2. As an isomer of the amino acid phenylalanine, it features in the biosynthesis of proteins. Known for its analgesic and antidepressant characteristics, D-Phenylalanine plays a crucial role in pharmaceutical and supplement industries. Despite being not naturally occurring, it can be produced in a lab setting and consumed as a dietary supplement. It's considered to inhibit the breakdown of endorphins, increasing the effects of endorphin-related natural pain relief within the body.

InChI:InChI=1/C11H15NO2/c12-10(11(13)14)8-4-7-9-5-2-1-3-6-9/h1-3,5-6,10H,4,7-8,12H2,(H,13,14)

Upstream product

• 4392-24-9 Cinnamyl bromide 
• 108019-30-3 DL-N-acetyl-2-amino-5-phenylpentanoic acid 

Downstream Products

• 1021707-70-9 3-MeOOC-Bzls-d-Ppg-OH 
• 1322746-50-8 (R)-2-benzylsulfonylamino-5-phenylpentanoic acid 
• 159635-47-9 (R)-2-(2-tert-butoxycarbonylamino-2-methyl-propionylamino)-5-phenyl-pentanoic acid 

Relevant articles and documents

Synthesis method of multi-configuration long-chain phenyl amino acid compound

The invention relates to a method for synthesizing a multi-configuration long-chain phenyl amino acid compound. The method comprises the following steps: reacting a compound shown in a formula I witha compound shown in a formula II or an isomer thereof in

STEREOSELECTIVE PROCESS FOR THE SYNTHESIS OF (D)-2-AMINO-5-PHENYLPENTANOIC OR ALKYL ESTER THEREOF

The present invention provides a process for preparing a compound of formula (I); wherein R is a C1-C6 alkyl; or a salt thereof; comprising:(c) hydrolyzing (D,L)-N-acetyl-2-amino-5-phenylpentanoic acid with a suitable base in the pre

Heterocyclic compounds

This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintanence of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of formula I.